Skip to main content
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc. — Investor Relations & Filings

Ticker · AVBP ISIN · US04272N1028 US Manufacturing
Filings indexed 130 across all filing types
Latest filing 2026-02-17 Major Shareholding Noti…
Country US United States of America
Listing US AVBP

About ArriVent BioPharma, Inc.

https://arrivent.com/

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy involves forging strategic collaborations to in-license and advance promising drug candidates for global patient populations. Its lead development candidate is firmonertinib, a novel therapeutic for cancer. ArriVent's pipeline also includes other oncology therapeutics, such as next-generation antibody drug conjugates. The company leverages its team's extensive drug development and regulatory experience to design development strategies with clear paths to approval, aiming to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
4 Filing
Director's Dealing
2026-02-04 English
4 Filing
Director's Dealing
2026-02-04 English
4 Filing
Director's Dealing
2026-02-04 English
4 Filing
Director's Dealing
2026-02-04 English
4 Filing
Director's Dealing
2026-02-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.